GGrantIndex
← Leaderboards

Celdara Medical, Llc

Lebanon, NH

Compare ↔
$48,979,934
Total funding
44
Grants

Funding over time

peak $5.6M · FY2009–25
$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$48,979,934 · 44

By mechanism

R44$30,557,792 · 15
R43$7,491,001 · 19
UT2$3,663,595 · 1
R42$2,949,803 · 1
R41$1,649,107 · 3
N43$1,422,630 · 3

Investigators at Celdara Medical, Llc

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Colleen Doyle Cooper$3,827,5023 gr2Julie H Coleman$1,301,0802 gr

Emerging Leaders

6–10 yrs in

1Joana M Murad$11,241,45010 gr2Jake Reder$1,721,5762 gr3Brandy Lynn Houser$1,127,8042 gr4Irena Ivanovska$523,0072 gr

All-Time

Most funded here, all years

1Joana M Murad$11,241,45010 gr2Colleen Doyle Cooper$3,827,5023 gr3Jake Reder$1,721,5762 gr4Julie H Coleman$1,301,0802 gr5Brandy Lynn Houser$1,127,8042 gr6Yolanda Camille Nesbeth$749,9991 gr7Irena Ivanovska$523,0072 gr8Carin Marie-Louise Sentman$413,4281 gr

Largest grants

ChNKG2D-Targeted Cellular Cancer Therapy: Phase I Clinical Trial$1,819,563
R44 · FY2013 · HL
DRIVEN: Accelerating Medical Entrepreneurship in the Northeast$1,466,246
UT2 · FY2019 · GM
DRIVEN: Accelerating Medical Entrepreneurship in the Northeast$1,451,724
UT2 · FY2020 · GM
ChNKG2D-Targeted Cellular Cancer Therapy: Phase I Clinical Trial$1,399,888
R44 · FY2012 · HL
Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma$1,228,902
R44 · FY2025 · CA
Depletion of Dendritic Cells by Immunotoxin as Therapy for Myocardial Infarction$1,070,291
R44 · FY2012 · HL
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome$1,000,000
R42 · FY2023 · AI
Development of GIFT4: a B cell focused immunotherapy for cancer$999,997
R44 · FY2018 · CA
Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes$999,828
R44 · FY2024 · DK
Preclinical development of an important, broad-spectrum antibody for pandemic influenza$999,635
R44 · FY2023 · AI
Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes$999,432
R44 · FY2023 · DK
Development of GIFT4: a B cell focused immunotherapy for cancer$999,088
R44 · FY2017 · CA
Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM$998,624
R44 · FY2020 · DK
Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas$998,375
R44 · FY2024 · AI
Depletion of Dendritic Cells by Immunotoxin as Therapy for Myocardial Infarction$998,051
R44 · FY2013 · HL
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome$993,938
R42 · FY2024 · AI
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus$984,986
R44 · FY2021 · AI
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus$974,351
R44 · FY2022 · AI
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus$962,825
R44 · FY2020 · AI
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome$955,865
R42 · FY2025 · AI